Nifeviroc
Based on 1 Customer Validation
Nifeviroc is an orally active CCR5 antagonist. Nifeviroc is used for the study of HIV type-1 infection.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.39%
- No. CAS: 934740-33-7
- Fòrmula: C33H42N4O6
- Peso molecular:590.71
-
Almacenamiento:
-20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-13004
MaravirocCCR5 Antagonist -
HY-14882
CenicrivirocCCR2/5 Antagonist -
HY-17377
Vicriviroc maleateCCR Antagonist -
HY-12080A
BX471 hydrochlorideCCR Antagonist -
HY-18611
Abaucin hydrochlorideCCR2antagonist -
HY-15418
RS 504393CCR2 Antagonist -
HY-12080
BX471CCR1 Antagonist -
HY-14882A
Cenicriviroc MesylateCCR2/5 Antagonist -
HY-119217
AZ084CCR8 Allosteric Antagonist -
HY-19974
TAK-220CCR Antagonist -
HY-13406
TAK-779CCR5 Antagonist -
HY-122219
R243CCR8 Antagonist
Actividad biológica
Descripciòn
IC50 & Target
[1]|
CCR5 |
HIV-1 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | IC50 |
2.9 nM
Compound: 1
|
Antagonist activity at CCR5 expressed in CHO cells assessed as inhibition of RANTES-induced [35S]GTPgamma binding by scintillation proximity assay
Antagonist activity at CCR5 expressed in CHO cells assessed as inhibition of RANTES-induced [35S]GTPgamma binding by scintillation proximity assay
|
[PMID: 20561788] |
| CHO | IC50 |
2.9 nM
Compound: 5
|
Inhibition of human CCR5 expressed in CHO cells assessed as inhibition of RANTES-stimulated [35S]GTPgammaS binding
Inhibition of human CCR5 expressed in CHO cells assessed as inhibition of RANTES-stimulated [35S]GTPgammaS binding
|
[PMID: 20674358] |
| CHO | IC50 |
3.5 nM
Compound: 1
|
Antagonist activity at CCR5 expressed in CHO cells assessed as inhibition of RANTES-induced calcium elevation
Antagonist activity at CCR5 expressed in CHO cells assessed as inhibition of RANTES-induced calcium elevation
|
[PMID: 20561788] |
Chemical Information
-
No. CAS 934740-33-7
-
Appearance Solid
-
Peso molecular 590.71
-
Fòrmula C33H42N4O6
-
Color Off-white to yellow
-
SMILES
O=C(OCC1=CC=C([N+]([O-])=O)C=C1)N(C2CCN(C[C@H]3CN(C(C4CCCC4)=O)C[C@]3(O)C5=CC=CC=C5)CC2)CC=C
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
-20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Solvente y solubilidad
In Vitro:
DMSO : 95 mg/mL (160.82 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.23 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocolo
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Pureza y Documentación
-
Ficha de datos (279 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.6929 mL | 8.4644 mL | 16.9288 mL | 42.3219 mL |
| 5 mM | 0.3386 mL | 1.6929 mL | 3.3858 mL | 8.4644 mL | |
| 10 mM | 0.1693 mL | 0.8464 mL | 1.6929 mL | 4.2322 mL | |
| 15 mM | 0.1129 mL | 0.5643 mL | 1.1286 mL | 2.8215 mL | |
| 20 mM | 0.0846 mL | 0.4232 mL | 0.8464 mL | 2.1161 mL | |
| 25 mM | 0.0677 mL | 0.3386 mL | 0.6772 mL | 1.6929 mL | |
| 30 mM | 0.0564 mL | 0.2821 mL | 0.5643 mL | 1.4107 mL | |
| 40 mM | 0.0423 mL | 0.2116 mL | 0.4232 mL | 1.0580 mL | |
| 50 mM | 0.0339 mL | 0.1693 mL | 0.3386 mL | 0.8464 mL | |
| 60 mM | 0.0282 mL | 0.1411 mL | 0.2821 mL | 0.7054 mL | |
| 80 mM | 0.0212 mL | 0.1058 mL | 0.2116 mL | 0.5290 mL | |
| 100 mM | 0.0169 mL | 0.0846 mL | 0.1693 mL | 0.4232 mL |
Nifeviroc Related Classifications
HY-111069 Related Classifications
Powered by Bioz